Virtual screening and molecular docking of Anti-Antileishmanial for selected pharmacophore for visceral Leishmaniasis
Abstract
Objective: DNA amplification of Cysteine protease of Leishmania donovani and study the interaction of cysteine protease inhibitors, antileishmanial compounds with cysteine protease receptor in various computational programs.
Materials and methods: Cysteine protease DNA of Leishmania donovani was amplified by PCR. The sequence of cysteine protease has been modeled and docked with suitable inhibitors by using various servers and computational tools. The model was designed, compared and validated by DOPE and Verify 3D scores. The model and the compound interaction were studied by LibDock and other programs.
Results: Cysteine protease DNA of Leishmania donovani was successfully amplified by PCR. The structural modeling was done to achieve effective enzyme inhibition, inhibitors block the binding sites of that protein. Homology modeling of cysteine protease has been done and docked with suitable inhibitors by using various servers and computational tools. The model was designed, compared and validated by DOPE and Verify 3D scores by using DSv3.5. Licochalcone-a alone showed 37 LibDock conformations with 6 different poses, were suitably docked at the site 1 with hydrogen bond formation. The study would help to design the novel drugs in respect of resistant one for the treatment of harmful visceral Leishmaniasis.
Conclusion: The molecular interaction of vinyl sulfones, hydrazide derivatives, antileishmanial drugs molecules and carbohydrazide derivatives have exhibited ideal molecular interaction with cathepsin B, a cysteine protease of L. donovani, amino acids such as Cys29, Hisl88 and Asn208 has been found to be active residues. Licochalcone-a and hydrazide derivative may become future antileishmanial compounds, which needs to be tested in in vitro and in vivo.
Keywords: Cysteine Protease, Vinyl Sulfone, Hydrazide, Antileishmanial Drugs, Licochalcone, Visceral Leishmaniasis.
DOI
https://doi.org/10.22270/jddt.v8i6-s.2120References
Murray HW, Berman JD, Davies CR, Saravia NG, “Advances in leishmaniasis,” The Lancet, 2005; 366(9496):1561–1577.
Handman E, “Leishmaniasis: current status of vaccine development,” Clin. Microbiol. Rev., 2001; 14(2):229–243.
Peters W, Evans DA, Lanham SM, Importance of parasite identification in cases of leishmaniasis. SAGE Publications Sage UK: London, England, 1983.
Prasad LSN, “Kala azar,” Indian J. Pediatr., 1999; 66(4):539–546, 1999.
Barral A et al., “Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease,” Am. J. Trop. Med. Hyg., 1991; 44(5):536–546.
Aggarwal P, Handa R, Singh S, Wali JP, “Kala-azar-new developments in diagnosis and treatment,” Indian J. Pediatr., vol. 66, no. 1, pp. 63–71, 1999.
Singh N, Curran MD, Rastogil AK, Middleton D, Sundar S, “Diagnostic PCR with Leishmania donovani specificity using sequences from the variable region of kinetoplast minicircle DNA,” Trop. Med. Int. Health, 1999; 4(6):448–453.
Bisti S, Konidou G, Papageorgiou F, eviève Milon G, Boelaert JR, Soteriadou K, “The outcome of Leishmania major experimental infection in BALB/c mice can be modulated by exogenously delivered iron,” Eur. J. Immunol., 2000; 30:12: 3732–3740.
Alvar J et al., “Leishmania and human immunodeficiency virus coinfection: the first 10 years,” Clin. Microbiol. Rev., 1997; 10(2):298–319.
Desjeux P, Alvar J, “Leishmania/HIV co-infections: epidemiology in Europe,” Ann. Trop. Med. Parasitol., 2003; 97(sup1):3–15.
Bernier R, Barbeau B, Tremblay MJ, Olivier M, “The lipophosphoglycan of Leishmania donovani up-regulates HIV-1 transcription in T cells through the nuclear factor-κB elements,” J. Immunol., 1998; 160(6):2881–2888.
Roberts WL, Hariprashad J, Rainey PM, Murray HW, “Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis,” Am. J. Trop. Med. Hyg., vol. 1996; 55(4):444–446.
Bogitsh BJ, Middleton OL, Ribeiro-Rodrigues R, “Effects of the antitubulin drug trifluralin on the proliferation and metacyclogenesis of Trypanosoma cruzi epimastigotes,” Parasitol. Res., vol. 1999; 85(6):475–480.
Herwaldt BL, Miltefosine—the long-awaited therapy for visceral leishmaniasis? Mass Medical Soc, 1999.
Rees PH, Kager PA, Wellde BT, Hockmeyer WT, “The response of Kenyan kala-azar to treatment with sodium stibogluconate,” Am. J. Trop. Med. Hyg., 1984; 33(3):357–361.
Salotra P, Singh R, “Challenges in the diagnosis of post kala-azar dermal leishmaniasis,” Indian J. Med. Res., 2006; 123(3):295.
Chatterjee AN, Ghosh JJ, “Transaminases of Leishmania donovani, the causative organism of kala-azar,” Nature, 1957; 180(4599):1425.
Bittencourt AL, Barral A, “Evaluation of the histopathological classifications of American cutaneous and mucocutaneous leishmaniasis,” Mem. Inst. Oswaldo Cruz, vol. 1991; 86(1):51–56.
Published
Abstract Display: 485 
PDF Downloads: 655 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.